Immuno Met Therapeutics
Biotechnology, 2450 Holcombe BLVD, Houston, Texas, 77021, United States, 1-10 Employees
Phone Number: +13*********
Who is IMMUNOMET THERAPEUTICS
ImmunoMet Therapeutics is a clinical stage biotech targeting cellular metabolism to develop novel anti-fibrotic and anti-tumor therapies. Our lead molecule, IM156, is a protein complex 1 ...
Read More
-
Headquarters: 2450 Holcombe BLVD, Houston, Texas, 77021, United States
-
Date Founded: 2015
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
Dean Welsch
Email
Phone
Industry: Biotechnology
SIC Code: 5122
Does something look wrong? Fix it. | View contact records from IMMUNOMET THERAPEUTICS
ImmunoMet Therapeutics Org Chart and Mapping
Similar Companies to ImmunoMet Therapeutics
Celltex Therapeutics Corporation
-
11-50
-
$ 1 Million to 5 Million
HanAll Biopharma
-
201-500
-
$ 1 Million to 5 Million
Iterion Therapeutics
-
11-50
-
$ 1 Million to 5 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding ImmunoMet Therapeutics
Answer: ImmunoMet Therapeutics's headquarters are located at 2450 Holcombe BLVD, Houston, Texas, 77021, United States
Answer: ImmunoMet Therapeutics's phone number is +13*********
Answer: ImmunoMet Therapeutics's official website is https://immunomet.com
Answer: ImmunoMet Therapeutics's revenue is $1 Million to $5 Million
Answer: ImmunoMet Therapeutics's SIC: 5122
Answer: ImmunoMet Therapeutics has 1-10 employees
Answer: ImmunoMet Therapeutics is in Biotechnology
Answer: ImmunoMet Therapeutics top competitors include: Celltex Therapeutics Corporation , HanAll Biopharma , Iterion Therapeutics
Answer: ImmunoMet Therapeutics contact info: Phone number: +13********* Website: https://immunomet.com
Answer: ImmunoMet Therapeutics is a clinical stage biotech targeting cellular metabolism to develop novel anti-fibrotic and anti-tumor therapies. Our lead molecule, IM156, is a protein complex 1 (PC1) inhibitor that targets the Oxidative Phosphorylation (OXPHOS) pathway in mitochondria and decreases aberrant cell growth in fibrosis and select cancer cells. IM156 is the first potent PC1 inhibitor to complete Phase 1 with a good tolerability. In fibrosis, ImmunoMet is currently conducting a Phase 1 study in healthy volunteers and plan to progress into Phase 2 PoC study in IPF patients in 4Q2021. The company was founded in 2015, is a spin-off from HanAll Biopharma, a Korean midsized public company, and has raised $31 MM post-spin-off.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month